Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H, Wang Y, Wang GQ. · 2020
Read Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. by Cheng H, Wang Y, Wang GQ. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7317908.txt.
Introduction
Cheng, Wang and Wang review the organ-protective role of ACE2 and what it means for COVID-19 prognosis. Their review appeared in the Journal of Medical Virology. ACE2 balances the renin-angiotensin system, countering the arm that raises blood pressure and damages tissue. It is spread widely through the heart, kidneys, lungs, and testes, and it guards against hypertension, diabetes, and cardiovascular disease.
SARS-CoV-2 uses ACE2 as its doorway into airway cells, which may strip away that protection. Poor outcomes cluster with male sex, age over 60 years, underlying disease, and secondary lung failure. The authors suggest that vaccines based on the spike protein and drugs that raise ACE2 activity are among the most promising treatment directions to pursue.
Catalog record
| CREATOR | Cheng H, Wang Y, Wang GQ. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19 By Hao Cheng, Yan Wang, Gui‐Qiang Wang Published in: Journal of Medical Virology DOI: 10.1002/jmv.25785 ABSTRACT Abstract This article reviews the correlation between angiotensin‐converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID‐19) and the possible mechanisms. ACE2 is a crucial component of the renin‐angiotensin system (RAS). The classical RAS ACE‐Ang II‐AT1R regulatory axis and the ACE2‐Ang 1‐7‐MasR counter‐regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS‐CoV, SARS‐CoV‐2 also uses the ACE2 receptor to invade human alveolar epithelial cells. Acute respiratory distress syndrome (ARDS) is a clinical high‐mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID‐19 is related to factors such as sex (male), age (>60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein‐based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID‐19 in the future. Keywords: acute respiratory distress syndrome (ARDS), angiotensin‐converting enzyme 2 (ACE2), coronavirus disease 2019 (COVID‐19), renin‐angiotensin system (RAS), severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) INTRODUCTION The renin‐angiotensin system (RAS) is a critical homeostasis regulation system of the human body (showed in Figure 1). 1 The ACE‐Ang II‐AT1R pathway is called the classical RAS axis, which plays a decisive role in regulation, while the ACE2‐Ang 1‐7‐MasR‐based pathway is called the counter‐regulatory RAS axis, which plays a negative role in regulation. 2 The primary role of the positive RAS axis is to increase sympathetic nervous system tension, cause vasoconstriction, increase blood pressure, and promote inflammation, fibrosis, and myocardial hypertrophy. The negative regulatory axis mediated by angiotensin‐converting enzyme 2 (ACE2) can antagonize these effects. In the RAS system, the same component can produce opposite physiological effects through different pathways, different components can also be linked by different pathways to have the same physiological effect. This flexibility helps the body respond quickly and coordinately to specific stimuli, from the whole body to a local area and plays an essential role in maintaining homeostasis. This paper will specifically examine the organ protection of ACE2 in the body and discuss its potential role for coronavirus disease 2019 (COVID‐19). [Figure: Classical and counter‐regulatory RAS. ACE, angiotensin‐converting enzyme; ACE2, angiotensin‐converting enzyme 2; Ang 1‐7, angiotensin 1‐7; Ang I, angiotensin I; Ang II, angiotensin II; Ang III, angiotensin III; AT1R, type 1 angiotensin II receptor; MasR, MAS proto‐oncogene receptor; RAS, renin‐angiotensin system] ANGIOTENSIN‐CONVERTING ENZYME 2 ACE2 is a homolog of ACE and was discovered in 2000. 3 Despite the similarities between ACE and ACE2, the functions of these two enzymes are entirely different. ACE2 is active in most tissues and is widely distributed in the heart, kidney, lung, and testis. 3 , 6 ACE2 is widely present in human alveolar epithelial cells and small intestinal epithelial cells, as well as in arterial and venous endothelial cells and arterial smooth muscle cells. Epidermal basal cell layer of skin and basal layer of the nonkeratinized squamous epithelium of nasal, oral mucosa, and nasopharynx have ACE2 expression. ACE2 is more strongly expressed in type II epithelial cells. Glomerular tubules show ACE2 low, glomerular mesangial and glomerular endothelial cells do not express ACE2, Kupffer cells and hepatocytes, spleen, thymus, lymph nodes, bone marrow, and B and T lymphocytes and macrophages do not show ACE2. 7 , 8 ACE2 tissue activity is higher than its plasma activity. 9 Its activity can not be inhibited by traditional angiotensin‐converting enzyme inhibitors (ACEIs). 3 ACE2 has a high affinity for Ang II, 10 and its catalytic efficiency for Ang II is 400 times greater than that for Ang I. ACE2 may show differences in different ages and sexes. 11 , 12 ACE2 AND ACUTE LUNG INJURY, SARS CORONAVIRUS Lung tissue has high RAS activity and is the leading site of Ang II synthesis. Ang II is an effective pulmonary vasoconstrictor. RAS is activated during hypoxia. Ang II can not only promote the growth response of vascular smooth muscle cells but also directly promote vascular remodeling and prevent pneumonia and shunts related to lung injury. 13 However, Ang II can also promote the occurrence of pulmonary edema and impair lung function. 14 Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury. It is characterized mainly by increased pulmonary vascular permeability and pulmonary edema. It is often induced by sepsis, aspiration, and pneumonia (including that caused by SARS coronavirus, bird flu, and human influenza viruses). It is a clinical, high‐death‐rate disease. ACE2 is highly expressed in the lung, and Imai et al 14 confirmed the protective effect of ACE2 in acute lung injury. The ACE2 protein in a mouse model induced by inhaled acidic gas was significantly downregulated, while the ACE level remained stable. The inhalation of acidic gas significantly increased the levels of Ang II in the lung and plasma of wild‐type mice, and the levels of Ang II in the lung and plasma of acid‐induced ACE2 knockout (ACE2 KO) mice were further increased. Recombinant human ACE2 (rhACE2) protein treatment could reduce plasma Ang II levels and reduce acute lung injury in ACE2 KO mice and wild‐type mice. A similar phenomenon was observed in a sepsis mouse model. Studies have further demonstrated that Ang II plays a role in acute lung injury via AT1R. ACE2 is also one of the primary receptors for SARS‐CoV invasion into the human body. 15 What is puzzling is that SARS‐CoV infection leads to highly lethal pneumonia compared with other common cold symptoms after other coronavirus infections. The researchers found that SARS‐CoV‐infected or recombinant SARS‐spike protein‐treated wild‐type mice exhibited significantly reduced ACE2 expression in the lungs. These mice showed increased severity of pathological conditions in acute lung injury. Treating ACE2 KO mice with SARS‐spike protein did not aggravate ARDS symptoms. Therefore, the downregulation of ACE2 expression in SARS‐CoV infection may play a causal role in the pathogenesis of SARS, which provides a reasonable explanation for the progression of SARS patients into ARDS. The recent outbreak‐causing novel coronavirus pneumonia (COVID‐19) virus (2019‐nCoV, SARS‐CoV‐2) has also been shown to invade human alveolar epithelial cells through mainly ACE2. 16 COVID‐19 ARDS patients and SARS patients have typical ARDS pathology in the lung. 17 We believe that SARS‐CoV‐2 and SARS‐CoV may share similar pathogenesis and pathological manifestations. RISK FACTORS FOR COVID‐19 PROGNOSIS AND ACE2 In the early outbreak of COVID‐19, epidemiological analyses of 99 patients 18 and 138 patients 19 showed that the average age of patients was close to 56 years and that the incidence of infections in men was higher than that of infections in women. Nearly half of the cases were complicated by chronic underlying diseases (hypertension, diabetes, cardiovascular disease, etc). A retrospective analysis of 52 cases of severely ill patients in Wuhan 20 suggested that the severely